Affiliations: [a] University Aix Marseille, Marseille, France | [b] CEO and Health Scientist, ENDEPUSresearch, Inc, USA | [c] President and Managing Director of StrategicMedicine
Correspondence:
[*]
Address for correspondence: Prof. C. Huttin, 1770 Massachusetts Avenue, Box 591, Cambridge, MA 02140, USA. E-mail: chris.huttin@comcast.net.
Abstract: This paper discusses the application of an adaptive technology platform to evaluate clinical pathways, clinical strategies and their application to early genetic testing in Europe. It results from a collaboration between Professor Christine Huttin, who created a technology startup called endepusresearchinc (www.endepusresearchinc-com) in Cambridge USA and Dr Michael Liebman, Managing Director of Strategic Medicine, Inc.(www.strategicmedicine.com) positioned in the translational medicine space with technologies to model disease processes and experience in early genetic testing for breast cancer. Diagnostics was identified as a potential area for application of economic and business models using ENDEPUSresearchinc statistical methods combining implicit and explicit financial information for prospective payment systems in various types of health care financing systems. The new economics resulting from such platforms challenges the constrained environment for public, private laboratories and partnerships, the restrictions imposed by governmental agencies, alliances between stakeholders such as the medical profession and laboratories: such early technologies are clearly identified as a key benefit to the system over time but a major challenge for short term returns.
Keywords: Early genetic testing, breast cancer, translational medicine, adaptive technology
